Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AUR108 · 1 trial · 1 indication
Assess dose limiliting toxicities of AUR108
Number of participants with TEAEs
Maximum Concentration of AUR108
Tmax in hours
Area under the curve (AUC) of AUR108 in h\* ng/mL
Terminal elimination half-life of AUR 108 in hours
Compare in fast and fed conditions
Compare Tmax in fast and fed conditions
Compare AUC in fast and fed conditions
| Arm | Type | Description |
|---|---|---|
| AUR108, 50mg to 300mg | EXPERIMENTAL | Currently, planned dose levels are 50,90,150,220,300 mg will be administered in 3+/4- regimen. |
| Name | Type | Description |
|---|---|---|
| AUR108 | DRUG | 3 Days dosing, and 4 days no dose in a week |
Inclusion Criteria: 1. Males or females ≥ 18 years of age 2. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1 3. Acceptable bone marrow and organ function at screening as described below: 1. ANC ≥ 1000/μL (without WBC growth factor support) 2. Platelet count ≥ 75,000/μL...
AUR108 is an investigational small molecule being developed for the treatment of relapsed advanced lymphomas. It is currently being evaluated in a Phase 1 clinical trial in patients with this condition. The drug is not yet approved and remains in clinical development.
AUR108 is a small molecule therapeutic being studied for relapsed advanced lymphomas. The specific molecular target of AUR108 has not been disclosed in available information. The drug is currently in Phase 1 clinical development.
AUR108 is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker symbol RDY. The company is conducting a Phase 1 clinical trial of AUR108 in patients with relapsed advanced lymphomas.
AUR108 is currently in Phase 1 clinical development. It is being studied in an open-label, uncontrolled trial in patients with relapsed advanced lymphomas. The drug is investigational and has not been approved by regulatory authorities.
AUR108 is being evaluated in a Phase 1 clinical trial with the identifier NCT05984147, titled 'A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)'. This trial is currently recruiting participants in India and aims to enroll 40 patients.
AUR108 is the designated name for this investigational drug being developed by Dr. Reddy's Laboratories Ltd. No alternative names for AUR108 have been disclosed in available information. It is currently in Phase 1 clinical trials for relapsed advanced lymphomas.